Revolution Medicines (RVMD)
$
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
About
Business overview of Revolution Medicines (RVMD)
Revolution Medicines Inc is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit elusive, frontier targets within notorious growth and survival pathways, with particular emphasis on the RAS and mTOR signaling pathways. The company's products includes RMC-4630, a SHP2 inhibitor, RAS(ON) portfolio, and SOS1 and 4EBP1/mTORC1 programs.
Key Insights
Critical company metrics and information
Share Price
$48.07Market Cap
$8.09 BillionTotal Outstanding Shares
168.22 Million SharesTotal Employees
490Dividend
No dividendIPO Date
February 13, 2020SIC Description
Biological Products, (no Disgnostic Substances)Homepage
https://www.revmed.com
Historical Stock Splits
Execution Date | Split Amount |
---|---|
No Historical Stock Splits |
Cash Flow Statement
October 1, 2023 to September 30, 2024
Metric | Value |
---|---|
Net Cash Flow From Financing Activities, Continuing | $924.96 Million |
Net Cash Flow | $-156.64 Million |
Net Cash Flow From Operating Activities | $-539.71 Million |
Net Cash Flow From Operating Activities, Continuing | $-539.71 Million |
Net Cash Flow From Investing Activities, Continuing | $-541.89 Million |
Net Cash Flow, Continuing | $-156.64 Million |
Net Cash Flow From Financing Activities | $924.96 Million |
Net Cash Flow From Investing Activities | $-541.89 Million |
Income Statement
October 1, 2023 to September 30, 2024
Metric | Value |
---|---|
Research and Development | $553.19 Million |
Net Income/Loss Available To Common Stockholders, Basic | $-567.06 Million |
Basic Average Shares | $341.23 Million |
Income Tax Expense/Benefit | $343000.00 |
Operating Income/Loss | $-653.20 Million |
Nonoperating Income/Loss | $86.48 Million |
Preferred Stock Dividends And Other Adjustments | $0.00 |
Net Income/Loss | $-567.06 Million |
Diluted Average Shares | $341.23 Million |
Income/Loss From Continuing Operations Before Tax | $-566.72 Million |
Basic Earnings Per Share | $3.66 |
Other Operating Expenses | $95.75 Million |
Revenues | $742000.00 |
Diluted Earnings Per Share | $3.66 |
Income/Loss From Continuing Operations After Tax | $-567.06 Million |
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
Net Income/Loss Attributable To Parent | $-567.06 Million |
Operating Expenses | $653.94 Million |
Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
Balance Sheet
October 1, 2023 to September 30, 2024
Metric | Value |
---|---|
Assets | $1.76 Billion |
Accounts Payable | $24.46 Million |
Noncurrent Liabilities | $85.83 Million |
Equity | $1.57 Billion |
Other Non-current Assets | $102.11 Million |
Noncurrent Assets | $183.86 Million |
Current Assets | $1.58 Billion |
Current Liabilities | $110.86 Million |
Equity Attributable To Parent | $1.57 Billion |
Equity Attributable To Noncontrolling Interest | $0.00 |
Liabilities | $196.69 Million |
Other Current Liabilities | $86.41 Million |
Intangible Assets | $56.94 Million |
Fixed Assets | $24.81 Million |
Liabilities And Equity | $1.76 Billion |
Historical Dividends
Announcement Date | Payment Date | Record Date | Amount | Frequency |
---|---|---|---|---|
No historical dividends |
Boost your savings and earn 4.35% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.
ⓒ 2024 Financhle. All Rights Reserved.